Purchase this article with an account.
Chae Eun Kim, Dong-Yoon Kum, Young-Joon Park, Yoonjin Lee, Byul-Nim Ahn, Jaewook Yang; Effect of cevimeline in ocular surface of dry eye mouse model. Invest. Ophthalmol. Vis. Sci. 2019;60(9):300.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
This study aimed to investigate the effects of various concentrations cevimelines (CVMs), and evaluated comparison with commercial drugs in a murine model of dry eye.
The experimental mouse model of dry eye was using NOD.B10.H2b mice by 30–40% ambient humidity and injection of scopolamine hydrobromide for 10 days. The clinical changes including to tear production, corneal irregularity, and fluorescein staining were measured by the instillation of various concentrations CVMs and commercial drugs for 10 days. The histological changes such as corneal detachment, conjunctival goblet cell and mucin density staining were stained by hematoxylin-eosin, periodic acid schiff, and alcian blue in the cornea or conjunctiva. The expression of inflammatory markers and mucin factors were detected by immunohistochemistry and immunofluorescence in the lacrimal gland, cornea, and conjunctiva.
In the CVM group tear production was increased, and similar to that in the diquafosol (DQS) and rebamipide (REB). The corneal smoothness and fluorescein staining score were improved, similar to that REB group in the CVM group. The corneal epithelial cells was decreased in the CVM group, and observed similar to the DQS and REB groups. The conjunctival goblet cells and mucin density were recovered in the CVM group, and similar to the cyclosporine (CsA) and REB groups. CVM showed suppress to the expression of inflammatory factors in the lacrimal gland, and up-regulation of mucin factors in the cornea and conjunctiva comparable to that with CsA and REB.
Instillation of CVM showed that the recovery or impovement of clinical and histological in the murine dry eye model, and all of the parameters observed comparable to that with commercial drugs.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only